Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 2/20 | 0.42 |
| ▸ | SI | P14410 | 2/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPRG | P23470 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490086 | 0.86 | MPO (0.48) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6641351 | 0.84 | SMN1; SMN2 (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6639259 | 0.82 | NPC1 (0.48) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6637294 | 0.81 | CYP1A2 (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL490008 | 0.81 | NPC1 (0.48) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1520900 | 0.80 | MPO (0.54) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6642311 | 0.79 | ALDH1A1 (0.46) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6635264 | 0.78 | MAPT (0.60) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6644471 | 0.78 | KMT2A (0.43) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL489860 | 0.76 | RAB9A (0.78) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| EP-1527051-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011443-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | KMT2A 3621/4885MEN1 3586/4885RAB9A 1335/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | KMT2A 3621/4885MEN1 3586/4885RAB9A 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.